K8 Shows Greater GA Growth Reduction Over Time

Clinical Scorecard: K8 Shows Greater GA Growth Reduction Over Time

At a Glance

Category	Detail
Condition	Geographic atrophy (GA) associated with age-related macular degeneration
Key Mechanisms	Kamuvudine K8 is an investigational inflammasome inhibitor delivered by intravitreal bioerodible implant; it is designed to retain inflammasome inhibition while eliminating antiviral activity and mitochondrial toxicity associated with the original drug class.
Target Population	Adults with bilateral GA; the phase 2 study enrolled 30 patients.
Care Setting	Multicenter US phase 2 clinical study with intravitreal treatment and masked reading-center assessment of GA lesion growth.

Key Highlights

In the primary analysis, K8 0.7 mg reduced GA growth rate by 54% compared with untreated fellow eyes.
A piecewise analysis of the 0.7-mg cohort found reductions of 43% during months 0 to 3 and 70% during months 3 to 6; the overall reduction was 56% (P=.0084).
Twenty-five of 30 participants had slower GA progression in the treated eye than in the untreated fellow eye.
In a prespecified subgroup with nonsubfoveal GA, adjusted BCVA favored K8 by 4 letters (P=.004); the study was not powered to assess visual acuity.
No drug-related serious adverse events or dose-limiting toxicities were reported through month 6; the small study limits conclusions about uncommon adverse events.

Guideline-Based Recommendations

Diagnosis

GA lesion growth was assessed by an independent reading center with masked readers.

Management

K8 was investigational in this phase 2 study; treated eyes received 0.3 mg, 0.7 mg, or 1.05 mg at baseline and month 3.
The article reports plans for a global phase 3 trial; it does not provide a clinical treatment recommendation.

Monitoring & Follow-up

The study assessed mean GA lesion growth rate and BCVA.
Safety observations through month 6 included serious adverse events, dose-limiting toxicities, endophthalmitis, intraocular inflammation, neovascular AMD, retinal vasculitis, and optic neuropathy.

Risks

No drug-related serious adverse events or dose-limiting toxicities were reported through month 6.
No cases of endophthalmitis, intraocular inflammation, neovascular AMD, retinal vasculitis, or optic neuropathy were observed.
The small study population limits conclusions about uncommon adverse events.

Patient & Prescribing Data

Thirty patients with bilateral GA were enrolled across 9 US centers. Each received K8 in the worse-seeing eye, with the untreated fellow eye serving as control.

The 30 treated eyes were divided among 0.3-mg, 0.7-mg, and 1.05-mg cohorts of 10 eyes each; doses were given at baseline and month 3. K8 uses a preloaded 24-gauge injector and bioerodible implant, with sustained delivery for approximately 3 months; the formulation does not require refrigeration.

Clinical Best Practices

Interpret the BCVA subgroup finding cautiously because the study was not powered to evaluate functional outcomes.
Interpret safety findings in light of the small sample and 6-month follow-up.
The study authors stated that a longer and larger study is needed to further assess the apparent increase in treatment effect over time and to validate functional benefits.